Thioproscaline
Pharmaceutical compound
From Wikipedia, the free encyclopedia
Thioproscaline (TP), or 4-thioproscaline (4-TP), also known as 3,5-dimethoxy-4-propylthiophenethylamine, is a psychedelic drug of the phenethylamine and scaline families related to mescaline.[1][2][3][4] It is the analogue of proscaline in which the propoxy group at the 4 position has been replaced with a propylthio group.[1][2][3]
- None
| |
| Clinical data | |
|---|---|
| Other names | TP; 4-Thioproscaline; 4-TP; 3,5-Dimethoxy-4-propylthiophenethylamine; 4-Propylthio-3,5-dimethoxyphenethylamine |
| Routes of administration | Oral[1] |
| Drug class | Serotonergic psychedelic; Hallucinogen |
| ATC code |
|
| Pharmacokinetic data | |
| Onset of action | >2 hours[1] |
| Duration of action | 10–15 hours[1] |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C13H21NO2S |
| Molar mass | 255.38 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
In his book PiHKAL (Phenethylamines I Have Known and Loved) and other publications, Alexander Shulgin lists thioproscaline's dose as 20 to 25 mg orally and its duration as 10 to 15 hours.[1][2][3] Its onset is more than 2 hours.[1] The drug has approximately 10 to 16 times the potency of mescaline.[2][3][4][1] The effects of thioproscaline have been reported to include extremely rich closed-eye imagery, quite a bit of open-eye visuals, body load, body heaviness, heavy pressure at the back of the neck, feeling vulnerable, dizziness, and hyperreflexia.[1][4] It was remarked that the psychoactive effects did not seem worth the physical side effects, although it was suggested that lower doses might be better.[1][4]
The chemical synthesis of thioproscaline has been described.[1][4]
Thioproscaline was first described in the scientific literature by Alexander Shulgin and Peyton Jacob III in 1984.[4] Subsequently, it was described in greater detail by Shulgin in PiHKAL in 1991.[1] The drug is not a controlled substance in Canada as of 2025.[5]